Claimed to be the first and only non-invasive gene expression diagnostic test, TruGraf Liver uses gene expression biomarkers to provide the latest and most accurate immune quiescence view.
This helps to confirm immune quiescence and rule out organ rejection.
The biomarkers deliver critical information to help guide clinical decision-making and personalise patient care.
The blood-based test helps clinicians confirm immune quiescence during the optimisation of immunosuppression in patients with stable graft function, reducing the risk of overt graft injury caused due to organ rejection.
It also enables a superior balance between adverse events and graft rejection.
According to the company, immunosuppressive medication is crucial to prevent organ rejection after liver transplants.
The use of immunosuppression has significant complications. To reduce the complications, clinicians can choose to minimise immunosuppression for liver transplant recipients.
Transplant Genomics noted that the optimisation of immunosuppression has largely been a ‘trial and error’ process until now, with clinicians depending on laboratory and clinical indicators of rejection and graft injury that result from the effects of immune activation.
Recently, another Eurofins subsidiary, Eurofins Genoma, introduced a non-invasive, preimplantation aneuploidy (niPGT-A) test for genetic screening.
The test allows medical practitioners to evaluate the chromosonal make-up of in vitro fertilisation (IVF) embryos and determine any chromosonal abnormalities that could cause complications during pregnancy.
This latest launch represents Eurofins Genoma’s commitment to the development of new tests.